产品
编 号：F750514
分子式：C22H19FN6
分子量：386.42
分子式：C22H19FN6
分子量：386.42
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 2247950-73-6
产品详情
生物活性：
KYN-101 is a potent, selective and orally active AHR inhibitor. KYN-101 decreases the CYP1A1 mRNA expression. KYN-101 shows anti-cancer activity.
体内研究：
KYN-101 (10 mg/kg；口服；每日一次，持续 12 天) 在小鼠体内显示出抗癌活性。Animal Model:6-8 weeks, C57BL/6J mice (B16IDO tumor-bearing mice)
Dosage:10 mg/kg
Administration:P.o.; daily for 12 days
Result:Reduced tumor growth in B16IDO tumor-bearing mice and combination of KYN-101 and anti-PD-1 led to improved tumor growth delay and extended survival in CT26 models.
体外研究：
KYN-101 (0.5, 1 μM; 24 h) 降低 IDOhigh 样本中的 CYP1A1 mRNA 表达。
KYN-101 is a potent, selective and orally active AHR inhibitor. KYN-101 decreases the CYP1A1 mRNA expression. KYN-101 shows anti-cancer activity.
体内研究：
KYN-101 (10 mg/kg；口服；每日一次，持续 12 天) 在小鼠体内显示出抗癌活性。Animal Model:6-8 weeks, C57BL/6J mice (B16IDO tumor-bearing mice)
Dosage:10 mg/kg
Administration:P.o.; daily for 12 days
Result:Reduced tumor growth in B16IDO tumor-bearing mice and combination of KYN-101 and anti-PD-1 led to improved tumor growth delay and extended survival in CT26 models.
体外研究：
KYN-101 (0.5, 1 μM; 24 h) 降低 IDOhigh 样本中的 CYP1A1 mRNA 表达。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备